To read more on this topic click here.
Inhalable drug given green light
Author: Simge Eva DoganPublished: 9 January 2019
Prep: Cook: Serves:
The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.
INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.
Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.
“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”
For more information on Parkinson’s medication please visit the EPDA website.
Share this story
Mouth-watering Michelin-starred meals for people with Parkinson’s
Delicious specialised recipes that meet your Parkinson's dietary needsREAD MORE
#UniteForParkinsons: the story so far
Highlights from #UniteForParkinsons 2017READ MORE
Telemedicine: how Sweden is reducing waiting times for Parkinson’s treatment
Video calling tech is speeding up access to advanced treatmentREAD MORE